Keros Therapeutics Inc (KROS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $196.83M
Last updated: Nov 17, 2026 at 4:34 PM ET
Keros Therapeutics Inc (KROS) Statistics
Keros Therapeutics (KROS) has a market cap of $196.83M. Its share count is down 51.05% from a year earlier. It kept -151.43% of revenue as net income over the last 12 months.
Total Valuation
| Market Cap | $196.83M |
|---|---|
| Latest price (Nov 17, 2026) | $11.31 |
Key Dates
The next earnings report is expected on Mar 2, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 2, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 5.5x and 0.8x. Its year-end P/S ranged from 3.4x to 177.7x from 2021 to 2025.
| P/S Ratio | 5.5x |
|---|---|
| Forward P/S | 4.8x |
| P/B Ratio | 0.8x |
Price Statistics
The stock is down 34.47% over 52 weeks and trades 2.72% above its 50-day average.
| Beta (1Y) | 1.19 |
|---|---|
| 52-Week Change | -34.47% |
| 1-Month Change | +2.26% |
| 3-Month Change | +1.89% |
| 6-Month Change | +14.13% |
| 5-Year Change | -73.54% |
| Total Return (1Y) | -34.47% |
| Total Return (3Y CAGR) | -27.98% |
| Total Return (5Y CAGR) | -28.77% |
| Return vs SPY (1Y) | -47.11% |
| Max Drawdown (1Y) | -58.01% |
| Max Drawdown (3Y) | -86.99% |
| Sharpe Ratio (1Y) | -0.83 |
| Correlation with SPY (1Y) | 0.31 |
| 50-Day Average | $11.01 |
| 200-Day Average | $11.55 |
| 52-Week Range | $8.98 to $22.55 |
| RSI (14 Days) | 58.1 |
| Average Volume (20 Days) | 202.11K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 18.14x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 18.14x |
|---|---|
| Quick Ratio | 18.14x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -22.12% over the last 12 months, against a 5-year average of -22.40%.
| Return on Equity (ROE) | -22.12% |
|---|---|
| Return on Assets (ROA) | -20.08% |
| ROE (5Y Average) | -22.40% |
| ROA (5Y Average) | -20.63% |
| ROIC (5Y Average) | 20.94% |
| Asset Turnover | 0.08x |
| Receivables Turnover | 4.08x |
Scores
KROS has an Altman Z-Score of 2.81, in the grey zone from 1.81 to 2.99, and a Piotroski F-Score of 6 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 2.81 |
|---|---|
| Altman Z Zone | Grey |
| Piotroski F-Score | 6 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $40.76M over the last 12 months is down 83.48% from the 12 months before.
| Revenue | $40.76M |
|---|---|
| Revenue Growth (YoY) | -83.48% |
| Gross Profit | $40.76M |
| Operating Income | -$73.27M |
| Pretax Income | -$62.47M |
| Net Income | -$61.73M |
| Reported EPS (TTM) | -$2.82 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 90.80% of the $307.37M in total assets.
| Cash and Equivalents | $259.46M |
|---|---|
| Total Debt | $0 |
| Net Cash | $259.46M |
| Net Cash Per Share | $13.05 |
| Working Capital | $271.78M |
| Shareholder Equity | $279.10M |
| Book Value Per Share | $14.03 |
| Total Assets | $307.37M |
| Total Liabilities | $28.27M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $421.00K of capital spending, operating cash flow left -$48.27M of free cash flow.
| Operating Cash Flow | -$47.85M |
|---|---|
| Capital Expenditures | $421.00K |
| Free Cash Flow | -$48.27M |
| FCF Per Share | -$2.43 |
| Depreciation and Amortization | $1.59M |
| Share Repurchases | $382.21M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -179.75%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -179.75% |
| Pretax Margin | -153.25% |
| Net Margin | -151.43% |
| FCF Margin | -118.43% |
Growth
| Book Value Per Share Growth (2Y CAGR) | -14.79% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | -14.79% |
Dividends and Yields
KROS does not pay a dividend. Its free cash flow yield is -21.46%.
| FCF Yield | -21.46% |
|---|---|
| Buyback Yield | 169.94% |
| Shareholder Yield | 169.94% |
Peer Position
Against 7 similar companies, KROS has the 6th highest P/S.
P/S RatioPeer median 11.8x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -68.74%
| P/S Ratio | 5.5x vs 11.8x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | -83.48% vs -68.74% median |
Analyst Forecast
Consensus estimates put revenue growth at -76.29% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -76.29% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About KROS
What is KROS's market cap?
Keros Therapeutics has a market cap of $196.83M.
How many shares of KROS are outstanding?
Keros Therapeutics has 19.89M shares outstanding. The count is down 51.05% from a year earlier.
Does KROS pay a dividend?
No. Keros Therapeutics does not pay a dividend.
How much debt does KROS have?
Keros Therapeutics has $0 of total debt and $259.46M of cash and equivalents, a net cash position of $259.46M.
KROS pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors